Navigation Links
Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
Date:5/2/2012

SAN DIEGO, May 2, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's Chief Commercial Officer Scott Byrd will present the company's corporate overview on Tuesday, May 8, 2012 at 4:50pm Eastern Time (1:50pm Pacific Time) during the Deutsche Bank Securities, Inc. 37th Annual Health Care Conference at the Intercontinental Boston Hotel in Boston.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 30 days.

About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting.  The current version of Cadence Pharmaceuticals' corporate overview may be viewed on the "Investors" page of www.cadencepharm.com, under "Events and Presentations."  Contacts:

William R. LaRueSVP, CFOCadence Pharmaceuticals, Inc.858-436-1400


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
2. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2011 Financial Results on August 3, 2011
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results on March 4, 2011
5. Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV™ (acetaminophen) Injection
6. Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
7. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
8. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
9. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
10. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
11. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Spartan Bioscience announced today that Health Canada ... It detects CYP2C19 genetic mutations in less than 60 ... RX CYP2C19 System is the first near-patient DNA test ... Due to the system’s ease of use, Health Canada ... professionals such as doctors, nurses, pharmacists, and laboratory technicians, ...
(Date:10/30/2014)... A new report, commissioned by BioCrossroads and conducted by ... at Indiana,s capital market and ... time frames: 1993 to 2002 and 2003 to 2013.  ... investment growth.  The Life Science Innovation Capital in ... innovation dollars as well as an increase in life ...
(Date:10/27/2014)... (PRWEB) October 27, 2014 The ... by Type (High & Medium), Sub-type (Primary & ... Processing, Infrastructure & Transportation & Power Generation) - ... the GIS market with analysis and forecasting of ... Market Data Tables with 52 Figures spread through ...
(Date:10/27/2014)... (PRWEB) October 27, 2014 New ... SoundConnect , an industry leading unified communication ... partners and agents to deliver cloud-based audio and ... growth opportunities. , With SoundConnect’s Q4 incentive ... twenty-five video and/or web conferencing licenses sold, now ...
Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 2New report shows Indiana's gains in life sciences innovation capital outpace the nation 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 4New report shows Indiana's gains in life sciences innovation capital outpace the nation 5Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4SoundConnect Unveils Q4 Partner Incentives 2
... Data and User Customization -- BUDAPEST, Hungary, August 20, 2010 ... ... ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
... Confirms Clinical Efficacy and Safety of Radioembolisation Using... -- BRUSSELS, August 19, 2010 ... ... --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
... Silence Therapeutics plc (AIM: SLN), a leading international RNAi ... Quark Pharmaceuticals, Inc. ("Quark"), has announced the grant of ... license to develop and commercialise QPI-1002, a p53 temporary ... Quark is currently conducting a Phase II clinical ...
Cached Biology Technology:ChemAxon Extends chemicalize.org Free Service With Predicted Data and User Customization 2ChemAxon Extends chemicalize.org Free Service With Predicted Data and User Customization 3ChemAxon Extends chemicalize.org Free Service With Predicted Data and User Customization 4ChemAxon Extends chemicalize.org Free Service With Predicted Data and User Customization 5ChemAxon Extends chemicalize.org Free Service With Predicted Data and User Customization 6Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 2Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 3Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 4Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 5Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 6Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy 7Silence Therapeutics' Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002 2
(Date:10/30/2014)... suite of technologies that can be used to enhance ... everything from search and rescue to service dogs to ... computer-mediated communication between humans and dogs that opens the ... and sending them clear and unambiguous cues in return," ... science at NC State and co-lead author of a ...
(Date:10/29/2014)... Research suggesting air pollutants released by unconventional oil and ... US is published today in the open access journal ... sulfide and formaldehyde were found. The study is the ... who live near production sites and could be used ... and gas come from reserves that do not readily ...
(Date:10/29/2014)... (October 29, 2014, Beaverton, OR) New research ... 11th International Conference in Houston, TX showed for ... eliminate HPV infection in women using a readily ... The study, presented by Dr. Judith A. Smith, ... Gynecology and Reproductive Sciences at The University of ...
Breaking Biology News(10 mins):New tech aims to improve communication between dogs and humans 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3HPV infections in women eradicated by AHCC, Japanese mushroom extract 2
... of Parkinson,s disease patients had insufficient levels of vitamin ... of Medicine. The fraction of Parkinson,s patients ... than patients with Alzheimer,s disease (41 percent) or healthy ... in the October issue of Archives of Neurology ...
... of their chimpanzee relatives, bonobo societyin which females enjoy ... of image. While chimpanzee males frequently band together to ... believed to restrict what meat they do eat to ... according to a study, reported in the October 14th ...
... of the brain can come under attack in patients with ... with an MS-like disease, the brain,s response to a protein ... cord or cerebellum that comes under fire. The studyfrom researchers ... and Washington University in St. Louiswill be published online on ...
Cached Biology News:Lack of vitamin D linked to Parkinson's disease 2Lack of vitamin D linked to Parkinson's disease 3Despite 'peacenik' reputation, bonobos hunt and eat other primates too 2
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
... been developed for use with immunohistochemical ... nonspecific background staining due to endogenous ... peroxidase with hydrogen peroxide. This ... with additional novel components to further ...
Rabbit polyclonal to Wilms Tumor Protein ( Abpromise for all tested applications). entrezGeneID: 7490 SwissProtID: P19544...
Ku80 Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: